Kerendia® finerenone

Summary of practical use guide

for the management of Heart Failure LVEF ≥40% in adults

NEW INDICATION

- Adult patients with **HF LVEF ≥40%***
- **Serum [K⁺] ≤5.0 mmol/L**
- **eGFR ≥25 mL/min/1.73m2**

Do not initiate treatment if:
serum [K⁺] is >5.0 mmol/L or eGFR <25 mL/min/1.73m²

DOSE INITIATION

eGFR (mL/min/1.73m²)	Starting dose	Target dose†
≥25 – <60	10 mg od	20 mg od
≥60	20 mg od	40 mg od

DOSE ADJUSTMENT

Serum [K+] mmol/L

Measure serum [K+] and eGFR **4 weeks** after initiating treatment or a dose adjustment. Adjust dose as needed

<5.0	**Increase to or maintain at target dose** (if eGFR has decreased by more than 30% compared with previous measurement, maintain current dose)
≥5.0 – <5.5	**Maintain at current dose**
≥5.5 – <6.0	**Decrease to previous dose (withhold if 10 mg od)**

If serum [K+] ≥6.0 mmol/L, withhold treatment. Restart at 10 mg od if serum [K+] <5.5 mmol/L‡

CONTRAINDICATIONS

In patients:

- with **hypersensitivity** to the drug components
- receiving concomitant treatment with **strong CYP3A4 inhibitors**
- with **Addison's disease**

WARNINGS AND PRECAUTIONS

- Can cause **hyperkalemia**§
- Can cause **worsening of renal function** in patients with HF§

Rarely, severe events have been reported

SERUM POTASSIUM [K⁺] AND eGFR MONITORING

Monitor serum [K+] and eGFR periodically throughout treatment

More frequent monitoring may be necessary for patients at risk for hyperkalemia

Monitor serum [K+] and eGFR 4 weeks after:

1. **Treatment initiation**
2. **Dose adjustment**

Reference:
1. Kerendia Summary of Product Characteristics

*for the treatment of symptomatic chronic heart failure with left ventricular ejection fraction (LVEF) ≥ 40% in adults;
†Increase to target dose 4 weeks after treatment initiation based on eGFR and serum [K+] thresholds;
‡If repeated serum [K+] measurements are ≥5.5 mmol/L, restart finerenone at 10 mg od when serum [K+] <5.0 mmol/L;
§Monitor serum [K+] and eGFR as advised.
CYP3A4, cytochrome P450 3A4; eGFR, estimated glomerular filtration rate; HF, heart failure; [K+], potassium; LVEF, left ventricular ejection fraction; od, once daily.

Prescribing information and adverse event reporting information for Kerendia® (finerenone) is available via the QR code on the right.

Either click here or scan the QR code for prescribing information and adverse event reporting information.

For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.

PP-KER-GB-0910 | April 2026